02 May 2003
Cloning and characterization of the bidirectional promoter regulating the expression of the human poly(ADP-ribose) glycohydrolase (PARG) and inner mitochondrial membrane translocase 23 (TIM23) genes
M. Meyer-Ficca, R. Meyer, E. Jacobson, M. JacobsonMed Sci Monit 2003; 9(1): 44-0 :: ID: 15107
Abstract
Poly(ADP-ribosyl)ation is a posttranslational protein modification mediated by a family of poly(ADP-ribose) polymerases (PARPs). It is a highly energy-consuming process which can ultimately lead to depletion of cellular NAD+ pools and thereby to cell death. Poly(ADP-ribose) glycohydrolase (PARG) is the only known cellular ADP-ribose polymer degrading enzyme, thus the turnover of poly(ADP-ribose) appears to be dependent on the availability of cellular PARG. By computational analysis of the genomic locus of the human PARG gene, we identified a 470 bp bidirectional putative common promoter for the PARG and the TIM23 genes. The complete promoter was amplified by PCR of genomic DNA of human CF3 fibroblasts, sequenced and cloned into the reporter plasmid pGFL, in both PARG and TIM23 orientations. Transfection of these reporter plasmids into HEK293 cells allowed the determination of the respective promoter activities. The TIM23 promoter showed a 3.7 fold higher activity than the PARG promoter, suggesting different expression levels for these proteins. TIM23 promoter activity reached 30% of a RSV promoter control plasmid, while PARG promoter activity was 10% of the control. Detailed analysis of the promoter sequence indicates the presence of putative binding sites for transcription factors NF-kB, c-ETS-1, CREBP, MyoD and SP1. Promoter mutants lacking different putative transcription factor binding sites are currently under investigation to further elucidate the regulation of PARG expression and the possibility of a coregulation of PARG and TIM23 expression.
Keywords: poly(ADP-ribose)glycohydrolase, PARG, inner mitochondrial membrane translocase 23, TIM23, bidirectional common promoter
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
14 Mar 2024 : Clinical Research
Renal Dysfunction Increases Risk of Adverse Cardiovascular Events in 5-Year Follow-Up Study of Intermediate...Med Sci Monit In Press; DOI: 10.12659/MSM.943956
15 Mar 2024 : Clinical Research
Impact of One-Lung Ventilation on Oxygenation and Ventilation Time in Thoracoscopic Heart Surgery: A Compar...Med Sci Monit In Press; DOI: 10.12659/MSM.943089
14 Mar 2024 : Clinical Research
Differential DHA and EPA Levels in Women with Preterm and Term Births: A Tertiary Hospital Study in IndonesiaMed Sci Monit In Press; DOI: 10.12659/MSM.943895
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952